-
ABOUT USSSY Group Limited is a large high-tech pharmaceutical enterprise with coordinated development of R&D and industrialization in multiple fields such as new drugs, generic drugs, characteristic APIs
-
INNOVATIONSSY Group Limited has built a relatively perfect scientific research and innovation system with the development mode of “production, learning, research, and application” of multi-disciplinary integration and multi-directional combination.
-
RECRUITIt has established high-level innovation platforms such as engineering laboratory and technology research center jointly with Chinese Academy of Sciences, and now has nearly 400 high-level talents in drug research, analysis and clinical research.
-
SUBSIDIARIESThe company has a diversified business development pattern of R&D, production and export of new drugs, generic drugs, characteristic APIs, advanced finished pharmaceutical products, biological preparations and pharmaceutical packaging materials.
-
CONTACTWe will continue to strengthen innovation-driven development, will vigorously encourage the integration of production and research, strengthen and improve the five domains: new drugs, biological drugs, traditional Chinese medicine, generic drugs and APIs
Shijiazhuang Sihua Pharmaceutical Group’s Hanlin Bio Showcases Its Excellence at the 90th China International Medical Equipment Fair
Category:
发布时间：2024-10-12
【概要描述】
At the recently opened 90th China International Medical Equipment Fair (CMEF), Shijiazhuang Sihua Pharmaceutical Group’s Hebei Hanlin Biotechnology Co., Ltd. made its debut at the show with a range of new products, drawing the attention of numerous industry professionals and exhibitors.
At the recently inaugurated 90th China International Medical Equipment Fair (CMEF), Hebei Hanlin Biotechnology Co., Ltd. of Shijiazhuang Sihua Pharmaceutical Group made its debut at the show with a range of new products, drawing the attention of numerous industry professionals and exhibitors.
According to reports, this year’s expo, themed “Innovative Technology, Smart Leadership for the Future,” was grandly held from October 12 to 15 at the Shenzhen International Convention and Exhibition Center, showcasing nearly 4,000 companies and tens of thousands of products from the global medical device industry. Over its 45-year history, CMEF has evolved into a comprehensive, global platform that spans the entire industrial value chain and product lifecycle, integrating product technology demonstrations, premier launches of new products, trade cooperation, and academic exchanges—earning it the reputation as a “barometer” of the global healthcare industry.
As a high-tech subsidiary of Shijiazhuang Sihua Pharmaceutical Group, Hanlin Bio has, in recent years, been driven by innovation, focused on cutting-edge market trends and precisely aligned with customer needs, and committed to becoming a technology-driven, innovative enterprise dedicated to the R&D, manufacturing, and sales of products in the biopharmaceutical, life sciences, and biotechnology sectors.
“At this exhibition, we are showcasing several recently developed, independently researched innovations, including a disinfectant medical ultrasound coupling gel, sterile saline nasal spray, medical sodium hyaluronate wound dressings, and a cardiac troponin test kit,” said a representative from Hanlin Bio. “By closely aligning with market needs and leveraging the Group’s robust R&D capabilities and our own comprehensive quality management system, we have focused on achieving breakthroughs in product development, quality control, and manufacturing processes, thereby continuously strengthening the Hanlin Bio brand.”
Currently, the Group’s Hanlin Bio has registered and launched for sale two Class I in vitro diagnostic reagents for nucleic acid collection and detection—namely, nucleic acid extraction or purification reagents and single-use viral sampling tubes—and has obtained approval for eight Class II medical device products, including disinfectant medical ultrasonic coupling agents, medical radiation protection sprays, medical liquid spray dressings, medical gynecological gels, sterile medical ultrasonic coupling agents, sterile saline nasal sprays, medical recombinant humanized collagen wound dressings, and medical sodium hyaluronate wound dressings. In addition, the company has one Class II in vitro diagnostic reagent product—the cardiac troponin I (cTnI) test kit (fluorescent immuno-chromatographic assay)—and is currently developing more than 20 additional Class II and Class III products. As a result, its portfolio of medical devices and biological products is steadily expanding and diversifying, with the company having secured four invention patents, 15 utility model patents, and 19 registered trademarks, thereby laying the foundation for a comprehensive greater-health product service system centered on medical devices and biological products.
At the exhibition, Hanlin Bio’s booth showcased a wide array of products that immediately caught the attention of business visitors and industry professionals, who stopped to inquire. Hanlin Bio’s staff warmly introduced the company’s latest R&D achievements to all attendees. Many exhibitors expressed strong interest in Hanlin Bio’s products and voiced their desire for business collaboration.
“Participating in the exhibition and engaging in exchanges with peers both domestically and internationally have broadened our horizons, deepened our understanding of industry development, and provided an excellent platform for showcasing our company and products, resulting in numerous collaboration opportunities,” said a representative from Hanlin Bio. “Going forward, we will continue to invest in R&D and innovation to develop more high-quality medical device products, thereby better rewarding and serving the trust and support of our valued customers.”
Keywords:
Recommended News
Share to
SERVICE HOTLINE
Address: Shimen Building, No. 8 Xingye Street, Shijiazhuang Economic and Technological Development Zone
Tel.: +86-311-67167130
Email: office@sjzsiyao.com
Mobile site
E code
Non-Commercial (Filing) – 2025-0091